These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 33588594)

  • 1. Dabigatran or Aspirin in East Asian Patients With Embolic Stroke of Undetermined Source: RE-SPECT ESUS Subgroup Analysis.
    Uchiyama S; Toyoda K; Lee BC; Liou CW; Wong LKS; Grauer C; Brueckmann M; Taniguchi A; Urano Y; Easton JD;
    Stroke; 2021 Mar; 52(3):1069-1073. PubMed ID: 33588594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS.
    Diener HC; Chutinet A; Easton JD; Granger CB; Kleine E; Marquardt L; Meyerhoff J; Zini A; Sacco RL
    Stroke; 2021 Mar; 52(3):1065-1068. PubMed ID: 33504190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups.
    Diener HC; Sacco RL; Easton JD; Granger CB; Bar M; Bernstein RA; Brainin M; Brueckmann M; Cronin L; Donnan G; Gdovinová Z; Grauer C; Kleine E; Kleinig TJ; Lyrer P; Martins S; Meyerhoff J; Milling T; Pfeilschifter W; Poli S; Reif M; Rose DZ; Šaňák D; Schäbitz WR
    Stroke; 2020 Jun; 51(6):1758-1765. PubMed ID: 32404035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS).
    Diener HC; Easton JD; Granger CB; Cronin L; Duffy C; Cotton D; Brueckmann M; Sacco RL;
    Int J Stroke; 2015 Dec; 10(8):1309-12. PubMed ID: 26420134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dabigatran vs. Aspirin for Secondary Prevention After Embolic Stroke of Undetermined Source　- Japanese Subanalysis of the RE-SPECT ESUS Randomized Controlled Trial.
    Toyoda K; Uchiyama S; Hagihara Y; Kuwashiro T; Mori T; Kamiyama K; Urano Y; Taniguchi A; Nozaki K; Cronin L; Grauer C; Brueckmann M; Diener HC
    Circ J; 2020 Nov; 84(12):2286-2295. PubMed ID: 33132228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial.
    Bahit MC; Sacco RL; Easton JD; Meyerhoff J; Cronin L; Kleine E; Grauer C; Brueckmann M; Diener HC; Lopes RD; Brainin M; Lyrer P; Wachter R; Segura T; Granger CB;
    Circulation; 2021 Nov; 144(22):1738-1746. PubMed ID: 34649459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.
    Diener HC; Sacco RL; Easton JD; Granger CB; Bernstein RA; Uchiyama S; Kreuzer J; Cronin L; Cotton D; Grauer C; Brueckmann M; Chernyatina M; Donnan G; Ferro JM; Grond M; Kallmünzer B; Krupinski J; Lee BC; Lemmens R; Masjuan J; Odinak M; Saver JL; Schellinger PD; Toni D; Toyoda K;
    N Engl J Med; 2019 May; 380(20):1906-1917. PubMed ID: 31091372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of Recurrent Stroke After Embolic Stroke of Undetermined Source in the RE-SPECT ESUS Trial.
    Del Brutto VJ; Diener HC; Easton JD; Granger CB; Cronin L; Kleine E; Grauer C; Brueckmann M; Toyoda K; Schellinger PD; Lyrer P; Molina CA; Chutinet A; Bladin CF; Estol CJ; Sacco RL
    J Am Heart Assoc; 2022 Jun; 11(11):e023545. PubMed ID: 35656979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual Antiplatelet Therapy After Embolic Stroke of Undetermined Source: A Subgroup Analysis of the CHANCE-2 Trial.
    Xie X; Jing J; Meng X; Johnston SC; Bath PM; Li Z; Zhao X; Wang Y; Xu Q; Wang A; Jiang Y; Li H; Wang Y;
    Stroke; 2024 Jul; 55(7):1739-1747. PubMed ID: 38860396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin: A Subgroup Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
    Merkler AE; Pearce LA; Kasner SE; Shoamanesh A; Birnbaum LA; Kamel H; Sheth KN; Sharma R
    JAMA Neurol; 2021 Dec; 78(12):1454-1460. PubMed ID: 34694346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical Trial.
    Veltkamp R; Pearce LA; Korompoki E; Sharma M; Kasner SE; Toni D; Ameriso SF; Mundl H; Tatlisumak T; Hankey GJ; Lindgren A; Berkowitz SD; Arauz A; Ozturk S; Muir KW; Chamorro Á; Perera K; Shuaib A; Rudilosso S; Shoamanesh A; Connolly SJ; Hart RG
    JAMA Neurol; 2020 Oct; 77(10):1233-1240. PubMed ID: 32628266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
    Shoamanesh A; Hart RG; Connolly SJ; Kasner SE; Smith EE; Martí-Fàbregas J; Liu YY; Uchiyama S; Mikulik R; Veltkamp R; O'Donnell MJ; Ntaios G; Muir KW; Field TS; Santo GC; Olavarria V; Mundl H; Lutsep H; Berkowitz SD; Sharma M
    JAMA Neurol; 2021 Jan; 78(1):11-20. PubMed ID: 33074284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.
    Kasner SE; Swaminathan B; Lavados P; Sharma M; Muir K; Veltkamp R; Ameriso SF; Endres M; Lutsep H; Messé SR; Spence JD; Nedeltechev K; Perera K; Santo G; Olavarria V; Lindgren A; Bangdiwala S; Shoamanesh A; Berkowitz SD; Mundl H; Connolly SJ; Hart RG;
    Lancet Neurol; 2018 Dec; 17(12):1053-1060. PubMed ID: 30274772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source: NAVIGATE-ESUS Trial.
    Mikulík R; Eckstein J; Pearce LA; Mundl H; Rudilosso S; Olavarría VV; Shoamanesh A; Chamorro Á; Martí-Fàbregas J; Veltkamp R; Öztürk Ş; Tatlisumak T; Peacock WF; Berkowitz SD; Connolly SJ; Hart RG
    Stroke; 2020 Jul; 51(7):2139-2147. PubMed ID: 32517582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis.
    Ntaios G; Swaminathan B; Berkowitz SD; Gagliardi RJ; Lang W; Siegler JE; Lavados P; Mundl H; Bornstein N; Meseguer E; Amarenco P; Cucchiara B; Camps-Renom P; Makaritsis K; Korompoki E; Papavasileiou V; Marti-Fabregas J; Milionis H; Vemmos K; Connolly SJ; Hart RG;
    Stroke; 2019 Sep; 50(9):2477-2485. PubMed ID: 31401971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial.
    Ntaios G; Pearce LA; Veltkamp R; Sharma M; Kasner SE; Korompoki E; Milionis H; Mundl H; Berkowitz SD; Connolly SJ; Hart RG;
    Stroke; 2020 Jun; 51(6):1797-1804. PubMed ID: 32295509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.
    Hart RG; Sharma M; Mundl H; Kasner SE; Bangdiwala SI; Berkowitz SD; Swaminathan B; Lavados P; Wang Y; Wang Y; Davalos A; Shamalov N; Mikulik R; Cunha L; Lindgren A; Arauz A; Lang W; Czlonkowska A; Eckstein J; Gagliardi RJ; Amarenco P; Ameriso SF; Tatlisumak T; Veltkamp R; Hankey GJ; Toni D; Bereczki D; Uchiyama S; Ntaios G; Yoon BW; Brouns R; Endres M; Muir KW; Bornstein N; Ozturk S; O'Donnell MJ; De Vries Basson MM; Pare G; Pater C; Kirsch B; Sheridan P; Peters G; Weitz JI; Peacock WF; Shoamanesh A; Benavente OR; Joyner C; Themeles E; Connolly SJ;
    N Engl J Med; 2018 Jun; 378(23):2191-2201. PubMed ID: 29766772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial.
    Kasner SE; Lavados P; Sharma M; Wang Y; Wang Y; Dávalos A; Shamalov N; Cunha L; Lindgren A; Mikulik R; Arauz A; Lang W; Czlonkowska A; Eckstein J; Gagliardi R; Amarenco P; Ameriso SF; Tatlisumak T; Veltkamp R; Hankey GJ; Toni DS; Bereczki D; Uchiyama S; Ntaios G; Yoon BW; Brouns R; DeVries Basson MM; Endres M; Muir K; Bornstein N; Ozturk S; O'Donnell M; Mundl H; Pater C; Weitz J; Peacock WF; Swaminathan B; Kirsch B; Berkowitz SD; Peters G; Pare G; Themeles E; Shoamanesh A; Connolly SJ; Hart RG;
    J Stroke Cerebrovasc Dis; 2018 Jun; 27(6):1673-1682. PubMed ID: 29525076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Embolic Stroke of Undetermined Source: Gateway to a New Stroke Entity?
    Schäbitz WR; Köhrmann M; Schellinger PD; Minnerup J; Fisher M
    Am J Med; 2020 Jul; 133(7):795-801. PubMed ID: 32247819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source.
    Scheitz JF; Pare G; Pearce LA; Mundl H; Peacock WF; Czlonkowska A; Sharma M; Nolte CH; Shoamanesh A; Berkowitz SD; Krahn T; Endres M;
    Stroke; 2020 Aug; 51(8):2386-2394. PubMed ID: 32640945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.